Explore Oxytocin dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Oxytocin is a nine-amino-acid neuropeptide synthesized in hypothalamic paraventricular and supraoptic nuclei, with FDA-approved IV / IM use as Pitocin in obstetric labor induction and postpartum hemorrhage, and an extensive intranasal off-label research literature in autism and social cognition. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with Oxytocin.
Oxytocin is a nine-amino-acid cyclic neuropeptide synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released both peripherally (from the posterior pituitary) and centrally (within the brain) as a neurotransmitter. The molecule's peripheral physiological role — uterine smooth muscle contraction during parturition and milk-ejection reflex during lactation — has been characterized for nearly a century, and synthetic oxytocin has been an FDA-approved drug under the brand name PITOCIN (Par Pharmaceutical) since the molecule was first synthesized by Vincent du Vigneaud at Cornell in 1953 (work that earned du Vigneaud the 1955 Nobel Prize in Chemistry). Pitocin is labeled for induction or augmentation of labor at term, control of postpartum hemorrhage, and management of incomplete or inevitable abortion via intravenous infusion or intramuscular injection.
Oxytocin is a nine-amino-acid hormone most often sourced for social-behavior, bonding, and reproductive research. It is FDA-approved as Pitocin and Syntocinon for labor and postpartum use. Research-grade oxytocin ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Oxytocin binds the oxytocin receptor (OXTR), a Gq-coupled GPCR expressed densely on uterine smooth muscle and mammary myoepithelial cells (driving the approved obstetric and lactation indications) and more sparsely throughout the central nervous system in regions including the amygdala, nucleus accumbens, hippocampus, and prefrontal cortex (driving the off-label social-bonding effects characterised in the social-neuroscience literature). Centrally acting oxytocin appears to modulate social cognition, trust, pair-bonding, and stress reactivity via the OXTR and via cross-talk with the vasopressin V1a receptor system.
Approved obstetric and lactation uses are well-established. The major contested off-label and research domain is centrally acting intranasal oxytocin for autism spectrum disorder, social anxiety, post-traumatic stress disorder, and pair-bonding research — characterised over two decades by the Carter, Young, Heinrichs, and Bartz groups. A 2021 multicentre Phase 2 RCT (SOARS-B, n=290) in autism was **negative**: intranasal oxytocin did not improve social or behavioural outcomes vs placebo.
Oxytocin has a reported half-life of ~3–5 min, and the dose intervals researchers model most often fall around as needed (intranasal). A half-life of only minutes means oxytocin clears almost instantly and never accumulates, so it is dosed acutely around when its effect is wanted. It is catalogued under Testosterone Peptides on WPA.
151 Oxytocin reconstitution calculations have been logged by the WPA community. The most common dose entered is 100mcg (32 calculations). The median dose across all sessions is 125mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (70 sessions). The most common dosing frequency is daily (7x/week) (6 logged protocols), followed by once weekly (5).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.